{"url_path":"/sec/gyre/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028564-index.html","accession_number":"0001140361-26-028564","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028564-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":272,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(a) Financial Statements of Business Acquired\n\nThe financial statements of Cullgen as of and for the three months ended March 31, 2026 and the year ended December 31, 2025, and the related notes thereto are attached as\nExhibit 99.1 and are incorporated herein by reference.\n\n(b) Pro Forma Financial Information\n\nThe unaudited pro forma condensed combined balance sheet of Gyre and Cullgen as of March 31, 2026 and the unaudited pro forma condensed combined statement\nof operations of Gyre and Cullgen for the three months ended March 31, 2026 and the year ended December 31, 2025 and 2024 and the related notes are attached as Exhibit 99.2 and are incorporated herein by reference.\n\n(d) Exhibits\n\nEXHIBIT INDEX\n\nExhibit\n\n \n\nDescription\n\n[23.1](ef20077460_ex23-1.htm)\n\n \n\nConsent of Ernst & Young Hua Ming LLP, independent registered public accounting firm of Cullgen Inc.\n\n[99.1](ef20077460_ex99-1.htm)\n\n \n\nFinancial statements of Cullgen Inc. as of and for the three months ended March 31, 2026 and the year ended December 31, 2025.\n\n[99.2](ef20077460_ex99-2.htm)\n\n \n\nUnaudited pro forma condensed combined balance sheet of Gyre Therapeutics, Inc. and Cullgen Inc. as of March 31, 2026 and the unaudited pro forma condensed\ncombined statement of operations for the three months ended March 31, 2026 and the years ended December 31, 2025 and 2024.\n\n104\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n \n\nGyre Therapeutics, Inc.\n\n \n\n \n\nDate: July 15, 2026\n\nBy:\n\n/s/ Ying Luo\n\n \n\nName:\n\nYing Luo\n\n \n\nTitle:\n\nChief Executive Officer"}